Abstract: This invention generally provides compounds, pharmaceutical compositions, and methods for their use, which include methods that result in increased expression in an Atoh1 gene (e.g., Hath1) in a biological cell. More specifically, the invention relates to the treatment of diseases and/or disorders that would benefit from increased Atoh1 expression, e.g., a hearing impairment or imbalance disorder associated with a loss of auditory hair cells, or a disorder associated with abnormal cellular proliferation.
Abstract: A method for visualizing structures inside a cochlea, comprising the steps of irradiating a cochlear bone with a first laser light to ablate portions of the cochlear bone, to form a thinned area of the cochlear bone, and imaging intracochlear structures by a second light via the thinned area of the cochlear bone to optically scan targeted structures inside the cochlea.
Type:
Grant
Filed:
April 13, 2017
Date of Patent:
September 14, 2021
Assignees:
ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL), MASSACHUSETTS EYE AND EAR INFIRMARY
Inventors:
Demetri Psaltis, Konstantina Stankovic, Donald Benjaman Conkey, Marilisa Romito
Abstract: Methods are described for predicting ancestral sequences for viruses or portions thereof. Also described are predicted ancestral sequences for adeno-associated virus (AAV) capsid polypeptides. The disclosure also provides methods of gene transfer and methods of vaccinating subjects by administering a target antigen operably linked to the AAV capsid polypeptides.
Type:
Grant
Filed:
December 17, 2019
Date of Patent:
August 31, 2021
Assignees:
The Schepens Eye Research Institute, Inc., Massachusetts Eye and Ear Infirmary
Abstract: The present invention relates to modified recombinant human MIS protein which has improved cleavage and increased bioactivity and increased potency as compared to wild-type human MIS protein. Other aspects of the invention relate to methods to prevent and treat cancers, such as cancers that express the MIS receptor type II (MISRII) by administering to a subject a composition comprising a recombinant human MIS protein. Another aspect of the present invention relates to methods to lower plasma androgen levels in a subject, and/or for the treatment of a subject with a disease characterized by excess androgen. Another aspect provides pharmaceutical compositions and kits and methods for use comprising a recombinant human MIS protein. Another aspect of the present invention relates to methods to decrease the dose of a chemotherapeutic agent by administering the chemotherapeutic agent with the recombinant MIS protein that lowers the effective dose of the chemotherapeutic agent.
Type:
Grant
Filed:
March 12, 2014
Date of Patent:
August 10, 2021
Assignees:
THE GENERAL HOSPITAL CORPORATION, MASSACHUSETTS EYE AND EAR INFIRMARY
Inventors:
Patricia K. Donahoe, Demetrios Vavvas, David Pepin, Mien Van Hoang
Abstract: The invention provides methods and polymer compositions for treating retinal detachment and other ocular disorders, where the methods employ polymer compositions that can form a hydrogel in the eye of a subject. The hydrogel is formed by reaction of (i) a nucleo-functional polymer that is a biocompatible polymer containing a plurality of thio-functional groups —R1—SH wherein R1 is an ester-containing linker, such as a thiolated poly(vinyl alcohol) polymer and (ii) an electro-functional polymer that is a biocompatible polymer containing at least one thiol-reactive group, such as a poly(ethylene glycol) polymer containing alpha-beta unsaturated ester groups.
Type:
Grant
Filed:
March 4, 2021
Date of Patent:
August 3, 2021
Assignee:
MASSACHUSETTS EYE AND EAR INFIRMARY
Inventors:
James Anthony Stefater, III, Tomasz Pawel Stryjewski
Abstract: Compositions are described for direct protein delivery into multiple cell types in the mammalian inner ear. The compositions are used to deliver protein(s) (such as gene editing factors) editing of genetic mutations associated with deafness or associated disorders thereof. The delivery of genome editing proteins for gene editing and correction of genetic mutations protect or restore hearing from genetic deafness. Methods of treatment include the intracellular delivery of these molecules to a specific therapeutic target.
Type:
Grant
Filed:
October 29, 2015
Date of Patent:
July 27, 2021
Assignees:
Massachusetts Eye and Ear Infirmary, President and Fellows of Harvard College
Inventors:
Zheng-Yi Chen, David R. Liu, Margie Li, David B. Thompson, John Zuris
Abstract: The disclosure features methods and systems that include: obtaining an input image of an imaging subject, where the input image is a color image featuring, in each of multiple color channels, a first set of pixel intensity values; for each one of the multiple color channels, determining a measured contrast value and a measured brightness value from the first set of pixel intensity values for the color channel, determining a contrast ratio for the color channel based on a target contrast value for the color channel and the measured contrast value for the color channel, and generating a second set of pixel intensity values for the color channel; and generating an output image of the imaging subject based on the second sets of pixel intensity values for each of the multiple color channels.
Type:
Grant
Filed:
March 5, 2018
Date of Patent:
June 29, 2021
Assignee:
Massachusetts Eye & Ear Infirmary
Inventors:
Edem Tsikata, Teresa C. Chen, Ines Maria de Carvalho Lains, Deeba Husain, John Miller
Abstract: This invention relates to methods for promoting reinnervation of auditory hair cells, specifically, by inhibiting Repulsive Guidance Molecule a (RGMa), a repulsive axonal guidance molecule that is expressed in the cochlea, or its receptor, neogenin.
Abstract: Methods for treating a human subject who has X-linked Retinitis Pigmentosa (XLRP) or another clinically-defined ophthalmological condition due to a loss-of-function mutation in the gene encoding the retinitis pigmentosa GTPase regulator (RPGR) protein, the method comprising administering to the subject a nucleic acid comprising an adeno-associated viral vector comprising an abbreviated human RPGR cDNA.
Type:
Grant
Filed:
June 10, 2019
Date of Patent:
June 29, 2021
Assignees:
Massachusetts Eye & Ear Infirmary, UCL Business Ltd., The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services
Inventors:
Michael A. Sandberg, Basil Pawlyk, Alan Finlay Wright, Xinhua Shu, Tiansen Li, Robin Ali
Abstract: The present invention provides a device or medical device comprising a graphene coating. Particularly, the graphene coating features substantially high transmittance, biointegrity and biocompatibility.
Type:
Application
Filed:
April 13, 2017
Publication date:
June 24, 2021
Applicants:
Massachusetts Eye and Ear Infirmary, Massachusetts Institute of Technology
Inventors:
Miguel Gonzalez ANDRADES, Paraskevi Evi KOLOVOU, Mahomed Mehdi GOULAMALY, Jing KONG, Tian MING
Abstract: The invention provides methods and polymer compositions for treating retinal detachment and other ocular disorders, where the methods employ polymer compositions that can form a hydrogel in the eye of a subject. The hydrogel is formed by reaction of (i) a nucleo-functional polymer that is a biocompatible polymer containing a plurality of thio-functional groups —R1—SH wherein R1 is an ester-containing linker, such as a thiolated poly(vinyl alcohol) polymer and (ii) an electro-functional polymer that is a biocompatible polymer containing at least one thiol-reactive group, such as a poly(ethylene glycol) polymer containing alpha-beta unsaturated ester groups.
Type:
Application
Filed:
March 4, 2021
Publication date:
June 24, 2021
Applicant:
Massachusetts Eye and Ear Infirmary
Inventors:
James Anthony STEFATER, III, Tomasz Pawel STRYJEWSKI
Abstract: Methods and compositions are provided that can be used to modify the assembly activating protein (AAP)-dependence of an adeno-associated virus (AAV).
Type:
Grant
Filed:
May 10, 2019
Date of Patent:
June 15, 2021
Assignees:
Massachusetts Eye and Ear Infirmary, The Schepens Eye Research Institute, Inc.
Inventors:
Luk H. Vandenberghe, Anna Claire Maurer
Abstract: The present disclosure relates to keratoprosthesis apparatuses comprising a flexible backplate and methods of manufacturing and implanting the new keratoprosthesis apparatuses. The keratoprosthesis apparatuses include a circular backplate composed, at least in part, of a titanium alloy. The circular backplate includes an annular rim portion having a central aperture extending therethrough. A plurality of tabs is positioned along the annular rim portion and extend radially inwardly into the aperture. A plurality of flexible appendages extends radially outwardly from the annular rim portion and is positioned along the annular rim portion at locations corresponding to the plurality of tabs.
Abstract: Provided herein are, inter alia, methods for treating rhinosinusitis with P-glycoprotein inhibitors. A subject having rhinosinusitis is identified and then treated by administration to the subject an effective amount of a P-gp inhibitor. The subject having rhinosinusitis can be identified by one of skill in the art based on known methods, e.g., based on detection of the presence of symptoms, by endoscopy, or by computed tomography. The efficacy of the treatment can be monitored by methods known in the art, e.g., by monitoring symptoms, by endoscopy or computed tomography. The P-glycoprotein inhibitor can be delivered to the subject's nasal passage and sinuses by an inhalation device, by flushing, by spraying, or by an eluting implant surgically placed in the subject's nasal passage or sinuses. The P-glycoprotein inhibitor can also be administered in combination with one or both of a corticosteroid and an antibiotic.
Abstract: The invention provides methods and polymer compositions for treating retinal detachment and other ocular disorders, where the methods employ polymer compositions that can form a hydrogel in the eye of a subject. The hydrogel is formed by reaction of (i) a nucleo-functional polymer that is a biocompatible polymer containing a plurality of thio-functional groups —R1—SH wherein R1 is an ester-containing linker, such as a thiolated poly(vinyl alcohol) polymer and (ii) an electro-functional polymer that is a biocompatible polymer containing at least one thiol-reactive group, such as a poly(ethylene glycol) polymer containing alpha-beta unsaturated ester groups.
Type:
Grant
Filed:
November 19, 2020
Date of Patent:
April 13, 2021
Assignee:
MASSACHUSETTS EYE AND EAR INFIRMARY
Inventors:
James Anthony Stefater, III, Tomasz Pawel Stryjewski
Abstract: The invention provides methods and polymer compositions for treating retinal detachment and other ocular disorders, where the methods employ polymer compositions that can form a hydrogel in the eye of a subject. The hydrogel is formed by reaction of (i) a nucleo-functional polymer that is a biocompatible polymer containing a plurality of thio-functional groups —R1—SH wherein R1 is an ester-containing linker, such as a thiolated poly(vinyl alcohol) polymer and (ii) an electro-functional polymer that is a biocompatible polymer containing at least one thiol-reactive group, such as a poly(ethylene glycol) polymer containing alpha-beta unsaturated ester groups.
Type:
Grant
Filed:
November 19, 2020
Date of Patent:
April 13, 2021
Assignee:
MASSACHUSETTS EYE AND EAR INFIRMARY
Inventors:
James Anthony Stefater, III, Tomasz Pawel Stryjewski
Abstract: The invention provides methods and polymer compositions for treating retinal detachment and other ocular disorders, where the methods employ polymer compositions that can form a hydrogel in the eye of a subject. The hydrogel is formed by reaction of (i) a nucleo-functional polymer that is a biocompatible polymer containing a plurality of thio-functional groups —R1—SH wherein R1 is an ester-containing linker, such as a thiolated poly(vinyl alcohol) polymer and (ii) an electro-functional polymer that is a biocompatible polymer containing at least one thiol-reactive group, such as a poly(ethylene glycol) polymer containing alpha-beta unsaturated ester groups.
Type:
Application
Filed:
November 19, 2020
Publication date:
March 18, 2021
Applicant:
Massachusetts Eye and Ear Infirmary
Inventors:
James Anthony STEFATER, III, Tomasz Pawel STRYJEWSKI
Abstract: The invention provides methods and polymer compositions for treating retinal detachment and other ocular disorders, where the methods employ polymer compositions that can form a hydrogel in the eye of a subject. The hydrogel is formed by reaction of (i) a nucleo-functional polymer that is a biocompatible polymer containing a plurality of thio-functional groups —R1—SH wherein R1 is an ester-containing linker, such as a thiolated poly(vinyl alcohol) polymer and (ii) an electro-functional polymer that is a biocompatible polymer containing at least one thiol-reactive group, such as a poly(ethylene glycol) polymer containing alpha-beta unsaturated ester groups.
Type:
Application
Filed:
November 19, 2020
Publication date:
March 18, 2021
Applicant:
Massachusetts Eye and Ear Infirmary
Inventors:
James Anthony STEFATER, III, Tomasz Pawel STRYJEWSKI
Abstract: The invention provides methods and polymer compositions for treating retinal detachment and other ocular disorders, where the methods employ polymer compositions that can form a hydrogel in the eye of a subject. The hydrogel is formed by reaction of (i) a nucleo-functional polymer that is a biocompatible polymer containing a plurality of thio-functional groups —R1—SH wherein R1 is an ester-containing linker, such as a thiolated poly(vinyl alcohol) polymer and (ii) an electro-functional polymer that is a biocompatible polymer containing at least one thiol-reactive group, such as a poly(ethylene glycol) polymer containing alpha-beta unsaturated ester groups.
Type:
Application
Filed:
November 19, 2020
Publication date:
March 18, 2021
Applicant:
Massachusetts Eye and Ear Infirmary
Inventors:
James Anthony STEFATER, III, Tomasz Pawel STRYJEWSKI